C12N 2795/14022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2795/14022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 14 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 13
- Assignees
- 17
- Inventors
- 54
- Latest grant
- 15 Aug 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal15 Aug 2023US 11,723,951 B2Amyl Therapeutics SRL
- Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal28 Jul 2020US 10,722,551 B2Proclara Biosciences, Inc.
- Antibacterial phage, phage peptides and methods of use thereof20 Jun 2017US 9,682,110 B2Technophage,Investigacao E Desenvolvimento Em Biotechnologia, SA
- Antibacterial phage, phage peptides and methods of use thereof15 Sep 2015US 9,134,312 B2Technophage, InvestigaçãO E Desenvolvimento Em Biotecnologia, SA
- Directed evolution of novel binding proteins22 Feb 2011US 7,893,007 B2Dyax Corp.
- Peptide targeting fusobacteria, composition for diagnosing cancer comprising same, and drug delivery composition5 Dec 2024US 2024/0402182 A1Industry-Academic Cooperation Foundation, Yonsei University
- M13 bacteriophage with a high cysteine content and genetically engineerable hydrogels28 Sep 2023US 2023/0304025 A1Massachusetts Institute of Technology
- Methods and compositions for killing a target bacterium3 Jun 2021US 2021/0161150 A1Locus Biosciences, Inc.
- Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal21 Jan 2021US 2021/0015895 A1Proclara Biosciences, Inc.
- Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal26 Jul 2018US 2018/0207231 A1Proclara Biosciences, Inc.
Most cited
By later US patents
- Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants660US 5,750,373 AGenentech, Inc. · 1998
- Surface expression libraries of heteromeric receptors586US 5,698,426 AIxsys, Inc. · 1997
- Monovalent phage display562US 5,821,047 AGenentech, Inc. · 1998
- Surface expression libraries of heteromeric receptors76US 5,871,974 AIxsys, Inc. · 1999
- Enrichment method for variant proteins with altered binding properties68US 6,040,136 AGenentech, Inc. · 2000